CTLA4 and neoplasm: Baseline or post-treatment changes in absolute leucocytes count (ALC), leucocytes sub-type counts, serum lactate dehydrogenase (LDH) and CRP levels, are among the most promising aim able to predict tumor response and survival in advanced melanoma patients treated with anti-PD-1 [30, 31] or anti-CTLA4 therapy [32–35].